• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
TDL 0.00% 27.0¢

TBG DIAGNOSTICS LIMITED - Charts / Financials

TBG Diagnostics Limited, formerly Progen Pharmaceuticals Limited, is a biotechnology... TBG Diagnostics Limited, formerly Progen Pharmaceuticals Limited, is a biotechnology company. The Company's principal activities include the discovery, research and development of pharmaceutical therapeutics for the treatment of human diseases, and the provision of contract services related to the process development, manufacture and quality assurance of biopharmaceutical products. The Company's segments include Research & Development, and Manufacturing. The Company is primarily engaged in the discovery and development of small molecule-based cancer therapeutics. The Company is focused on the development of the anti-angiogenesis and anti-metastatic oncology products pipeline. The Company's offerings include Muparfostat (PI-88) and PG545. Muparfostat (PI-88) is an anti-angiogenesis and anti-metastatic compound. Muparfostat (PI-88) is a dual angiogenesis and heparanase inhibitor. PG545 is an agent designed to target the tumor microenvironment.More

refresh Created with Sketch. REFRESH
Day
Open 0.0¢   Day High 0.0¢   Day Low 0.0¢
Daily Volume 0
Bids   Sellers
Number Price Volume   Number Price Volume
0 0.0¢ 0   0 0.0¢ 0

Directors & Senior Management

Mr. Indrajit Solomon Arulampalam Executive Chairman of the Board
Mr. Leslie Tillack Chief Executive Officer - Pharmasynth
Willy Hsu Chief Operating Officer
Mr. Lee Horobin General Manager - Finance
Dr. Keith Dredge Director of Drug Development
Ms. Fleur Lankesheer Director - Business Development and Legal
Mr. Justyn Stedwell Company Secretary
Dr. Shi-Chung Chang Non-Executive Director
Ms. Emily Lee Non-Executive Director
Mr. Bing-Cheng Liu Non-Executive Director

Data source: Refinitiv

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.